ghk-cu antibody formation or immunogenicity — Research Peptide, Third-Party Tested Injections Barrière — Wear your BAC Water:3ML

ghk-cu antibody formation or immunogenicity — Research Peptide, Third-Party Tested Injections Barrière — Wear your BAC Water:3ML

Barrière — Wear your Vitamins

BPC-157 is not FDA approved as a standard medication, and the FDA has identified concerns around compounded BPC-157, including possible immunogenicity risk, peptide-related impurities, and limited safety information for certain routes of administration

Injections

BAC Water:3ML

Expected timeline: Month 1-2: Inflammation management, symptomatic improvement Month 3-6: Potential slowing of degenerative markers, quality of life improvement Month 6-12: Assessment of structural changes, protocol optimization Ongoing: Maintenance protocols as needed, cycling strategies Complementary approaches: Anti-inflammatory nutrition